- Home
- LXFR vs GALT Comparison
LXFR vs GALT Comparison
Compare LXFR & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXFR | GALT |
|---|---|---|
| Founded | 1898 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.6M | 397.3M |
| IPO Year | 2002 | 2008 |
Fundamental Metrics
Financial Performance| Metric | LXFR | GALT |
|---|---|---|
| Price | $17.24 | $3.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | ★ $16.70 | N/A |
| AVG Volume (30 Days) | ★ 427.6K | 187.8K |
| Earning Date | 10-28-2026 | 11-17-2026 |
| Dividend Yield | ★ 3.02% | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $384,600,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.99 | N/A |
| P/E Ratio | $50.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.26 | $2.03 |
| 52 Week High | $19.45 | $7.13 |
Technical Indicators
Market Signals| Indicator | LXFR | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 45.24 |
| Support Level | $17.19 | $2.71 |
| Resistance Level | $17.38 | $4.10 |
| Average True Range (ATR) | 0.04 | 0.22 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 42.11 | 43.15 |
Price Performance
Historical ComparisonAbout LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is engaged in materials engineering and the manufacture of materials, components, and gas containment products. The company has two reportable segments: Elektron and Gas Cylinders. The Elektron segment produces specialty materials based on magnesium and zirconium for applications in aerospace, defense, automotive, and industrial markets. The Gas Cylinders segment manufactures high-pressure gas containment products using aluminum alloys and carbon composite technologies for use in healthcare, emergency response, aerospace, and alternative fuel transportation markets.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.